The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

Kennedy calls for banning hundreds of food additives and chemicals. He has called for getting ultra-processed foods out of ...

Debate over childhood obesity treatments: weight-loss drugs vs. lifestyle changes, with concerns about long-term effects.

Your favorite toys and weight-loss drugs could be priced out of reach if Donald Trump is serious. Denmark’s defiant message ...

US regulators believe that Novo Nordisk’s new long-acting, once-a-day insulin, Tresiba, has a notable, but uncertain, cardiovascular risk. An initial assessment, based on a pooled analysis ...

diabetes and heart disease: Rybelsus, Ozempic and Wegovy. These negotiations would have to be implemented by the Trump ...

we used a temporary price dislocation caused by disappointing clinical trial results to purchase shares of Novo Nordisk A/S (NYSE:NVO), a Danish-based leader in diabetes and obesity treatments.

Ozempic becomes the first GLP-1 treatment option for people with type 2 diabetes and chronic kidney disease Mario Tama/Getty The Food and Drug Administration has approved Ozempic to reduce the ...

According to Novo Nordisk, over 40% of persons with type 2 diabetes have chronic renal disease, which affects roughly 37 million adults in the United States. Last year, the FDA authorized Wegovy ...

FILE PHOTO: A handout photo shows a nine-month supply of Novo Nordisk's diabetes drug Ozempic stored in a refrigerator in London ...